Previous Close | 269.38 |
Open | 265.72 |
Bid | 269.97 x 100 |
Ask | 270.13 x 100 |
Day's Range | 265.72 - 271.68 |
52 Week Range | 211.71 - 329.72 |
Volume | |
Avg. Volume | 2,949,077 |
Market Cap | 144.811B |
Beta (5Y Monthly) | 0.60 |
PE Ratio (TTM) | 21.60 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 9.00 (3.33%) |
Ex-Dividend Date | May 16, 2024 |
1y Target Est | N/A |
Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia
Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT.
Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.